IHS Chemical Week

Regions :: Western Europe :: U.K.

Lonza and Eclipse Therapeutics Sign Development and Manufacturing Deal

12:03 AM MST | February 29, 2012 | Deepti Ramesh

Lonza says it has signed an agreement with private biotechnology company Eclipse Therapeutics (San Diego, CA) for the production of Eclipse’s novel cancer therapeutic antibody, ET-101, using Lonza’s light path development services. ET-101 is under investigation for the inhibition of the growth of cancer stem cells. Lonza will produce phase 1 clinical material at its development and manufacturing facility at Slough, U.K., under the deal. Cancer stem cells are a small subset of cells within a tumor that are thought to play a critical role in tumor...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa